Evidence map›Paper›PMID 29020387›Full record

ArticleThe international journal of neuropsychopharmacology2018

Reversal of Stress-Induced Social Interaction Deficits by Buprenorphine.

Caroline A Browne, Edgardo Falcon, Shivon A Robinson, Olivier Berton, Irwin Lucki

Open access · goldAbstract read
In one paragraph

Article in The international journal of neuropsychopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 57 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. The opioid system in depression.Neuroscience and biobehavioral reviews · 2022
    Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Caroline A BrowneDepartments of Psychiatry, Philadelphia, Pennsylvania.
Edgardo FalconDepartments of Psychiatry, Philadelphia, Pennsylvania.
Shivon A RobinsonDepartments of Psychiatry, Philadelphia, Pennsylvania.
Olivier BertonDepartments of Psychiatry, Philadelphia, Pennsylvania.
Irwin LuckiDepartments of Psychiatry, Philadelphia, Pennsylvania.
Philadelphia University · US

Funding

University of Pennsylvania Postdoctoral Opportunities in Research and TeachingK12GM081259 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI Janis K. Burkhardt · 2007 to 2026
$20.1M
TRAINING PROGRAM IN NEUROPSYCHOPHARMACOLOGY-PREDOCTORALT32MH014654 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI BERRETTINI, WADE H · 1985 to 2021
$5.0M
Buprenorphine for Depression and AnxietyR01MH092412 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI LUCKI, IRWIN · 2012 to 2016
$2.0M
Kappa Receptor Antagonists as Rapid Acting AntidepressantsR01MH105623 · NIMH · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI LUCKI, IRWIN · 2016 to 2019
$1.5M
NIGMS NIH HHS K12 GM081259NIMH NIH HHS R01 MH092412NIMH NIH HHS R01 MH105623NIMH NIH HHS T32 MH014654
6 · The paper itself

Abstract

Background: Patients with post-traumatic stress disorder frequently report persistent problems with social interactions, emerging after a traumatic experience. Chronic social defeat stress is a widely used rodent model of stress that produces robust and sustained social avoidance behavior. The avoidance of other rodents can be reversed by 28 days of treatment with selective serotonin reuptake inhibitors, the only pharmaceutical class approved by the U.S. Food and Drug Administration for treating post-traumatic stress disorder. In this study, the sensitivity of social interaction deficits evoked by 10 days of chronic social defeat stress to prospective treatments for post-traumatic stress disorder was examined. Methods: The effects of acute and repeated treatment with a low dose of buprenorphine (0.25 mg/kg/d) on social interaction deficits in male C57BL/6 mice by chronic social defeat stress were studied. Another cohort of mice was used to determine the effects of the selective serotonin reuptake inhibitor fluoxetine (10 mg/kg/d), the NMDA antagonist ketamine (10 mg/kg/d), and the selective kappa opioid receptor antagonist CERC-501 (1 mg/kg/d). Changes in mRNA expression of Oprm1 and Oprk1 were assessed in a separate cohort. Results: Buprenorphine significantly reversed social interaction deficits produced by chronic social defeat stress following 7 days of administration, but not after acute injection. Treatment with fluoxetine for 7 days, but not 24 hours, also reinstated social interaction behavior in mice that were susceptible to chronic social defeat. In contrast, CERC-501 and ketamine failed to reverse social avoidance. Gene expression analysis found: (1) Oprm1 mRNA expression was reduced in the hippocampus and increased in the frontal cortex of susceptible mice and (2) Oprk1 mRNA expression was reduced in the amygdala and increased in the frontal cortex of susceptible mice compared to non-stressed controls and stress-resilient mice. Conclusions: Short-term treatment with buprenorphine and fluoxetine normalized social interaction after chronic social defeat stress. In concert with the changes in opioid receptor expression produced by chronic social defeat stress, we speculate that buprenorphine's efficacy in this model of post-traumatic stress disorder may be associated with the ability of this compound to engage multiple opioid receptors.

Indexed as

Social BehaviorAnimalsBehavior, AnimalBrainBuprenorphineDisease Models, AnimalExcitatory Amino Acid AntagonistsFluoxetineKetamineMaleMiceMice, Inbred C57BLNarcotic AntagonistsReceptors, Opioid, kappaReceptors, Opioid, muSelective Serotonin Reuptake InhibitorsBuprenorphineExcitatory Amino Acid AntagonistsFluoxetineKetamineNarcotic AntagonistsReceptors, Opioid, kappaReceptors, Opioid, muSelective Serotonin Reuptake InhibitorsbuprenorphineCERC-501chronic social defeat stressfluoxetineketaminePTSDsocial interaction

Identifiers

PMID29020387
PMCPMC5793841
OpenAlexW2753036652

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.